One size fits all, or do we have to rethink optimal programming in implantable cardioverter-defibrillators implanted for secondary prevention?

Affiliations

Editorial

Ivan Cakulev et al. Heart Rhythm O2. 2020.

. 2020 May 16;1(2):83-84.

doi: 10.1016/j.hroo.2020.05.001. eCollection 2020 Jun.

¹ University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio.

No abstract available

Comment on

Implantable cardioverter-defibrillator programming after first occurrence of ventricular tachycardia in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).
Aktas MK, Bennett AL, Younis A, Kutyifa V, Polonsky B, McNitt S, Zareba W, Rosero S, Goldenberg I. Aktas MK, et al. Heart Rhythm O2. 2020 May 11;1(2):77-82. doi: 10.1016/j.hroo.2020.04.001. eCollection 2020 Jun. Heart Rhythm O2. 2020. PMID: 34113861 Free PMC article.

1. Sears S.F., Todaro J.F., Lewis T.S., Sotile W., Conti J.B. Examining the psychosocial impact of implantable cardioverter defibrillators: a literature review. Clin Cardiol. 1999;22:481–489. - PMC - PubMed
1. Kraaier K., Starrenburg A.H., Verheggen R.M., van der Palen J., Scholten M.F. Incidence and predictors of phantom shocks in implantable cardioverter defibrillator recipients. Neth Heart J. 2013;21:191–195. - PMC - PubMed
1. Tan V.H., Wilton S.B., Kuriachan V., Sumner G.L., Exner D.V. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2014;7:164–170. - PubMed
1. Pinski S.L., Fahy G.J. The proarrhythmic potential of implantable cardioverter-defibrillators. Circulation. 1995;92:1651–1664. - PubMed
1. Klein R.C., Raitt M.H., Wilkoff B.L. AVID Investigators. Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electrophysiol. 2003;14:940–948. - PubMed